What Disqualifies You From Taking Semaglutide? Contraindications & Who Shouldn't Take It (2026)

Only a short list of conditions truly disqualifies you from semaglutide. Per the FDA prescribing information for Wegovy and Ozempic on DailyMed, semaglutide is contraindicated in just three situations: a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and a serious hypersensitivity reaction to semaglutide or any of its ingredients.^[1][2] Those are the genuine "you cannot take this" items. Everything else you have read about — a history of pancreatitis, gallbladder disease, diabetic retinopathy, gastroparesis, type 1 diabetes, pregnancy, depression, or kidney problems — is a caution or a relative consideration that your prescriber weighs case by case, not an automatic disqualifier. This guide separates the absolute contraindications from the cautions, explains the BMI-based eligibility rules for weight management, and gives you a clear summary table. This is general educational information, not medical advice — your prescriber individualizes eligibility after reviewing your full history.

The short answer: who absolutely cannot take semaglutide

The FDA label lists only three absolute contraindications for semaglutide — the situations in which it should not be prescribed at all.^[1][2] Two of them are linked to the drug's boxed warning, the FDA's strongest safety alert, which is based on a finding in rodents that semaglutide caused thyroid C-cell tumors (including medullary thyroid carcinoma). Whether this risk carries over to humans is not known, but the precaution is firm:

• Personal or family history of medullary thyroid carcinoma (MTC). If you or a close family member has had this specific, relatively rare thyroid cancer, semaglutide is contraindicated. This is the human-relevant counterpart of the rodent C-cell tumor finding behind the boxed warning.^[1][2]
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 is an inherited condition that markedly raises the lifetime risk of medullary thyroid carcinoma, so it is an absolute contraindication for the same reason.^[1][2]
• Serious hypersensitivity to semaglutide or any excipient. If you have had a serious allergic reaction — such as anaphylaxis or angioedema — to semaglutide or to any inactive ingredient in the product, you must not take it again.^[1][2]

These three are the true disqualifiers. If none of them applies to you, you are not automatically ruled out — but several other conditions, covered next, can make you a poor candidate or call for extra caution and monitoring. For the thyroid boxed warning in depth, see our dedicated guide on semaglutide and thyroid risk.

Cautions: conditions that may make you a poor candidate

Beyond the three contraindications, the §5 Warnings and Precautions section of the semaglutide label flags a set of conditions that do not flatly disqualify you but require your prescriber to weigh the risk carefully, sometimes choose a different treatment, or monitor you closely.^[1][2] These are relative considerations — the decision is individualized.

• History of pancreatitis. Acute pancreatitis has been reported with semaglutide. The drug was not studied in people with a prior history of pancreatitis, so a clinician may be more cautious, choose another option, or watch closely if you have had it before. See our guide on semaglutide and pancreatitis.^[1]
• Diabetic retinopathy. In people with type 2 diabetes and a history of diabetic retinopathy, rapid improvement in blood sugar has been associated with a temporary worsening of retinopathy, so the label advises monitoring. This is mainly relevant to the diabetes (Ozempic) population.^[1]
• Severe gastrointestinal disease or gastroparesis. Semaglutide slows stomach emptying. It has not been studied in people with severe gastrointestinal disease, including severe gastroparesis (a stomach-paralysis condition), so it is generally not recommended in those situations.^[1]
• Gallbladder disease. Gallbladder problems, including gallstones (cholelithiasis), have been reported. A history of gallbladder disease is a reason for added caution and counseling, not an automatic bar.^[1]
• Type 1 diabetes. Semaglutide is not indicated for type 1 diabetes and has not been studied as a treatment for it; it is intended for type 2 diabetes (Ozempic) or chronic weight management (Wegovy).^[2]
• Pregnancy, planning pregnancy, or breastfeeding. Semaglutide is not recommended in pregnancy because animal data showed fetal harm, and weight loss offers no benefit during pregnancy. Because the drug has a long half-life, the label advises stopping it at least 2 months before a planned pregnancy. Breastfeeding is not recommended with Wegovy tablets; for the injection, the label asks you and your clinician to weigh the benefits of breastfeeding against your need for the drug.^[1][2]
• History of suicidal thoughts or depression. This is not a labeled precaution any more. The FDA struck the suicidal-behavior-and-ideation subsection from the Wegovy label in February 2026 after pooling 91 placebo-controlled trials in 107,910 patients and finding no increased risk^[5]. It is still worth raising at intake: a good prescriber screens for active depression, watches mood during titration, and the FDA continues to ask patients to report new or worsening symptoms^[5].
• Severe kidney impairment. The gastrointestinal side effects (vomiting, diarrhea) can cause dehydration, which can in turn lead to acute kidney injury. People with kidney problems need extra caution and attention to hydration.^[1][2]

The honest framing is that almost everything on this list is a relative consideration, not a hard stop. A prescriber reviews your full medical history, your current medications, and your goals before deciding whether semaglutide is appropriate for you. The general side-effect picture that drives several of these cautions is covered in our Ozempic side effects guide.

Summary table: absolute vs caution

Eligibility: who qualifies for semaglutide for weight management

Not being disqualified is only half the question. To be a candidate for Wegovy (semaglutide for chronic weight management), you also have to fit the §1 Indications and Usage section of the label, which covers adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity.^[1] The label itself prints no BMI numbers. In practice, prescribers apply the CDC's adult definition of obesity and the entry criteria of the STEP 1 trial that supported the approval, which means adults who have:^[6][4]

• A body mass index (BMI) of 30 or higher (obesity), or
• A BMI of 27 or higher (overweight) together with at least one weight-related health condition — for example high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

Wegovy is also approved for adolescents aged 12 years and older with obesity (defined by an age- and sex-specific BMI at or above the 95th percentile), and it carries an indication to reduce the risk of major cardiovascular events in certain adults with established cardiovascular disease and either obesity or overweight.^[1] In the pivotal STEP-1 trial that supported the weight-management approval, adults taking semaglutide 2.4 mg lost roughly 15% of body weight on average over 68 weeks, versus about 2.4% on placebo — the magnitude benchmark that defines what the drug does at its labeled dose.^[4]

Eligibility for the diabetes version of semaglutide differs. Ozempic is indicated to improve blood sugar in adults with type 2 diabetes (and to reduce cardiovascular risk in type 2 diabetics with known heart disease), so the qualifying condition there is the diabetes diagnosis, not a BMI threshold.^[2] If your goal is weight loss specifically, the BMI criteria above are the relevant test. The bottom line: you qualify if you meet the BMI rule, you have no absolute contraindication, and your prescriber judges the cautions above to be manageable in your case.

Most disqualifiers are relative — a clinician decides

The most important takeaway is that the genuine, no-exceptions disqualifiers are short: medullary thyroid carcinoma history, MEN 2, and serious hypersensitivity. Almost every other concern you have seen described as a "disqualifier" — pancreatitis, gallbladder disease, kidney problems, depression, gastrointestinal conditions — is a relative caution that a prescriber individualizes after reviewing your history, your other medications, and your goals.^[1][2] Some of those cautions will lead a clinician to choose a different medication; others are managed with monitoring and careful titration.

This article is general education, not a substitute for that personalized review. The way to get a real answer for your situation is a proper medical evaluation. If you want to start that process under proper supervision, compare the best semaglutide providers — legitimate providers screen you for the contraindications and cautions above before prescribing, which is exactly the safeguard that makes treatment appropriate. Your prescriber, not a checklist, makes the final eligibility decision. New to GLP-1s? Start with who qualifies for GLP-1 weight-loss medication.